Thomas J Vogl, Andrea Tröger, Simon Bernatz, Timo Stöver, Hamzah Adwan
{"title":"经动脉化疗灌注治疗头颈部恶性肿瘤的疗效和安全性。","authors":"Thomas J Vogl, Andrea Tröger, Simon Bernatz, Timo Stöver, Hamzah Adwan","doi":"10.1007/s11547-025-02039-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate tumor response and overall survival (OS) of patients with head and neck malignancies treated by transarterial chemoperfusion (TACP).</p><p><strong>Materials and methods: </strong>This monocentric retrospective study included a total of 77 patients with head and neck malignancies, who were at least treated by one session of TACP in palliative-intent between 2002 and 2021. Tumor response to therapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Local control was defined as achieving either partial response (PR) or stable disease (SD).</p><p><strong>Results: </strong>All 77 enrolled patients (mean age: 59 ± 12 years; 52 males) were analyzed according to OS. RECIST was performed in 70 out of 77 patients since follow-up imaging was not available in 7 patients. No major complications were observed. Considering RECIST, PR was achieved in 48.57% and SD in 44.29% of the patients, resulting in a local control rate of 92.86%. A total of 5 patients showed progressive diseases at a rate of 7.14%. The median OS was 12.6 ± 1.5 months. Patients with T1-T3 tumors had significantly longer OS compared to patients with T4.</p><p><strong>Conclusion: </strong>Palliative TACP has the potential to improve local tumor control and achieve remarkable survival outcomes for patients with head and neck area malignancies.</p>","PeriodicalId":20817,"journal":{"name":"Radiologia Medica","volume":" ","pages":"1254-1262"},"PeriodicalIF":4.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367814/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of transarterial chemoperfusion for head and neck malignancies.\",\"authors\":\"Thomas J Vogl, Andrea Tröger, Simon Bernatz, Timo Stöver, Hamzah Adwan\",\"doi\":\"10.1007/s11547-025-02039-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate tumor response and overall survival (OS) of patients with head and neck malignancies treated by transarterial chemoperfusion (TACP).</p><p><strong>Materials and methods: </strong>This monocentric retrospective study included a total of 77 patients with head and neck malignancies, who were at least treated by one session of TACP in palliative-intent between 2002 and 2021. Tumor response to therapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Local control was defined as achieving either partial response (PR) or stable disease (SD).</p><p><strong>Results: </strong>All 77 enrolled patients (mean age: 59 ± 12 years; 52 males) were analyzed according to OS. RECIST was performed in 70 out of 77 patients since follow-up imaging was not available in 7 patients. No major complications were observed. Considering RECIST, PR was achieved in 48.57% and SD in 44.29% of the patients, resulting in a local control rate of 92.86%. A total of 5 patients showed progressive diseases at a rate of 7.14%. The median OS was 12.6 ± 1.5 months. Patients with T1-T3 tumors had significantly longer OS compared to patients with T4.</p><p><strong>Conclusion: </strong>Palliative TACP has the potential to improve local tumor control and achieve remarkable survival outcomes for patients with head and neck area malignancies.</p>\",\"PeriodicalId\":20817,\"journal\":{\"name\":\"Radiologia Medica\",\"volume\":\" \",\"pages\":\"1254-1262\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367814/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiologia Medica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11547-025-02039-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologia Medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11547-025-02039-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Efficacy and safety of transarterial chemoperfusion for head and neck malignancies.
Purpose: To evaluate tumor response and overall survival (OS) of patients with head and neck malignancies treated by transarterial chemoperfusion (TACP).
Materials and methods: This monocentric retrospective study included a total of 77 patients with head and neck malignancies, who were at least treated by one session of TACP in palliative-intent between 2002 and 2021. Tumor response to therapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Local control was defined as achieving either partial response (PR) or stable disease (SD).
Results: All 77 enrolled patients (mean age: 59 ± 12 years; 52 males) were analyzed according to OS. RECIST was performed in 70 out of 77 patients since follow-up imaging was not available in 7 patients. No major complications were observed. Considering RECIST, PR was achieved in 48.57% and SD in 44.29% of the patients, resulting in a local control rate of 92.86%. A total of 5 patients showed progressive diseases at a rate of 7.14%. The median OS was 12.6 ± 1.5 months. Patients with T1-T3 tumors had significantly longer OS compared to patients with T4.
Conclusion: Palliative TACP has the potential to improve local tumor control and achieve remarkable survival outcomes for patients with head and neck area malignancies.
期刊介绍：
Felice Perussia founded La radiologia medica in 1914. It is a peer-reviewed journal and serves as the official journal of the Italian Society of Medical and Interventional Radiology (SIRM). The primary purpose of the journal is to disseminate information related to Radiology, especially advancements in diagnostic imaging and related disciplines. La radiologia medica welcomes original research on both fundamental and clinical aspects of modern radiology, with a particular focus on diagnostic and interventional imaging techniques. It also covers topics such as radiotherapy, nuclear medicine, radiobiology, health physics, and artificial intelligence in the context of clinical implications. The journal includes various types of contributions such as original articles, review articles, editorials, short reports, and letters to the editor. With an esteemed Editorial Board and a selection of insightful reports, the journal is an indispensable resource for radiologists and professionals in related fields. Ultimately, La radiologia medica aims to serve as a platform for international collaboration and knowledge sharing within the radiological community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
